Yes—the personalized mRNA #melanoma vaccine i just heard about has just reported positive Phase 3 results. It’s called intismeran autogene (also known as #mRNA‑4157 or V940) and is being developed by #Moderna and Merck.
It’s made for an individual patient using the genetic fingerprint of their melanoma.
In the trial, it was given after surgery, alongside #Keytruda, to people with higher-risk melanoma.
Among 1,137 participants, the combination lowered the relative risk of the melanoma returning or death by 42% compared with Keytruda alone. At two years, about 82% of people on the combination were alive without recurrence, compared with 70% on Keytruda alone.
A couple of important details:• The trial met its main goals, but researchers are still following patients to assess longer-term outcomes, including overall survival. • It’s for certain patients with melanoma removed by surgery—it’s not a preventive shot for everyone or a treatment for ordinary basal-cell or squamous-cell skin cancers. • It’s not yet an approved, generally available treatment; the companies say they’re discussing regulatory submissions. • The $12,000 figure is probably for Keytruda, not the experimental vaccine. Merck lists Keytruda at $12,517.44 per dose every three weeks (or $25,034.88 for its six-week dose); that’s the list price, and most insured patients don’t pay that full amount. The vaccine’s price hasn’t been announced.

